甲状腺癌分子诊断技术的研究进展被引量：9

Research Progress of Molecular Diagnostic Techniques of Thyroid Cancer

导出

摘要近年来,甲状腺癌发病率呈上升趋势,尤其在女性中,是最常见的内分泌恶性肿瘤之一。大量关于甲状腺癌的分子生物学变异被发现和定义,许多分子标记物能为甲状腺癌的风险评估提供依据,并具有优化手术治疗的潜能,为甲状腺癌患者提供更好的预后管理。如甲状腺癌相关基因BRAF突变的研究最为广泛,另外许多研究也对RAS,RET/PTC,和PAX8/PPARγ等基因的诊断价值进行了充分的评估。数据显示,这些标记物具有重要的诊断价值,有利于肿瘤的诊断以及作为潜在的治疗靶标。这篇综述讨论了甲状腺癌中最常见的分子遗传学变异及其临床意义,并评估了其诊断和预后的应用价值。 Thyroid cancer is the most common type of endocrine malignancy and its incidence is steadily increasing,especially in women.In the recent years,a large number of molecular alterations in thyroid cancer has been discovered and characterized.The knowledge of molecular genetics and alterations known to occur in thyroid cancer has been expanded and found dramatically.Some molecular markers,such as the BRAF mutation has been studied most extensively,provide evidences in risk stratification and can be potentially used to optimize surgical and postsurgical management of patients with thyroid cancer.Moreover,several studies also demonstrated diagnostic utilities of RAS,RET/PTC,and PAX8/PPARγmutations.Some of these markers may have significant diagnostic utility,can be used for tumor prognostication,and serve as potential therapeutic targets.This review discusses the most common molecular alterations in thyroid cancer and clinical significance,such as diagnostic and prognostic utility.

作者孙思陈创李艳

机构地区武汉大学人民医院检验科

出处《武汉大学学报（医学版）》 CAS 2016年第1期167-172,共6页 Medical Journal of Wuhan University

基金武汉大学自主科研项目(编号:2042015kf0111)

关键词甲状腺癌分子诊断基因突变 BRAF Thyroid Cancer Molecular Diagnosis Gene Mutation BRAF

分类号 R4 [医药卫生—临床医学] R73 [医药卫生—肿瘤]

引文网络
相关文献

参考文献16

1Santoro M, Carlomagno F. Central Role of RET in Thyroid Cancer[J]. Cold Spring Harb Perspect Biol, 2013, 5(12) :a009233.
2Scollo C, Russo M, De Gregorio L, et al. A novel RET gene mutation in a patient with apparently sporad- ic pheochromocytoma[J]. Endoer J, 2015, [Epub a- head of print].
3American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer management guidelines of the American Thyroid Asso- ciation[J]. Thyroid, 2009, 19:565-612.
4Guerra A, Zeppa P, Bifulco M, et al. Concomitant BRAF V600E Mutation and RET/PTC Rearrangement Is a Frequent Occurrence in Papillary Thyroid Carcino- ma[J]. Thyroid. 2014, 24(2): 254-259.
5Marotta V, Guerra A, Sapio M,et al. RET/PTC rear- rangement in benign and malignant thyroid diseases: a clinical standpoint [J]. Eur J Endocrinol, 2011, 165 : 499-507.
6Nikiforov YE. Molecular analysis of thyroid tumors[J] Mod Pathol, 2011,24:S34-S43.
7Cantwell ER, O ' Leary J J, Sheils OM, et al. BRAFV600E: implications for carcinogenesis and mo lecular therapy[J]. Mol Cancer Ther, 2011,10(3) : 385 394.
8Chiosea S, Nikiforova M, Zuo H, et al. A novel eom plex BRAF mutation detected in a solid variant of papil lary thyroid carcinomaEJ2. Endocr Pathol, 2009, 20: 122-126.
9Elisei R, Viola D, Torregrossa L, et al. The BRAFV600E mutation is an independent, poor prog- nostic factor for the outcome of patients with low risk intrathyroid papillary thyroid carcinoma., single-Institu- tion results from a large cohort study[J]. J Clin Endo crinol Metah, 2012, 97(12):4 390-4 398.
10Hershman JM. Mutations of the RAS oncogene are found in follicular variant papillary thyroid carcinoma [J]. Clin Thyroidol, 2013, 25:170-171.